

## Real Patients – Real Results

### Case #1:

73 year-old male


*OD disciform scar OS*

#### Treatment Plan:

*Meso- 10 mg; Zea- 2 mg;*


*Lut- 10 mg*

Before MacuHealth



20/30

After 9 Months



20/20

### Case #2:

Reduction in Drusen

#### Treatment Plan:

*Meso- 10 mg; Zea- 2 mg;*

*Lut- 10 mg*

Before MacuHealth



20/50 - 1

After 12 Months



20/30 + 2

### Case #3:


Reduction in Drusen

#### Treatment Plan:

*Meso- 10 mg; Zea- 2 mg;*


*Lut- 10 mg*

Before MacuHealth



June 2009

After 3 years



November 2012

## MacuHealth:

- *Simple Focused Formula- 3 month supply/ 1 small soft-gel daily*
- *Only formula containing all 3 natural macular antioxidants in the ideal ratio for optimum Macular Health and AMD protection<sup>(6)</sup>*
- *10mg- Meso-Zeaxanthin (MZ)/ 10mg Lutein/2 mg Zeaxanthin*
- *Meso-Zeaxanthin (MZ) is the strongest individual macular anti-oxidant<sup>(2)</sup>*
- *The combination of these three anti-oxidants represents the most potent macular anti-oxidant. More potent than any individual component<sup>(2)</sup>*
- *MacuHealth helps optimize serum bioavailability of circulation macular carotenoids for capture by retinal tissue<sup>(7)</sup>*
- *Safe, Stable formula with no contraindications<sup>(4)</sup>*
- *Statistically Significant improvement in Macular Pigment Optical Density (MPOD) and visual performance in terms of contrast sensitivity, visual acuity, and glare<sup>(1,5,6)</sup>*



## Sample Peer-Reviewed Scientific Publications:

1. Connolly EE, Beatty S, Thurnham DI, et al. Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study. Curr Eye Res. 2010;35:335-351.  
<http://www.ncbi.nlm.nih.gov/pubmed/20373901>
2. Bernstein, PS, MD, Li, B, Ahmed, F. Studies on the singlet oxygen scavenging mechanism of human macular pigment. Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT. Arch Biochem Biophys. Dec 2010; 1;504(1):56-60 <http://www.ncbi.nlm.nih.gov/pubmed/20678467>
3. Sabour-Pickett S, Nolan JM, Loughman J, Beatty S. A review of the evidence germane to the putative protective role of the macular carotenoids for age-related macular degeneration. Mol Nutr Food Res. 2011;10.  
<http://www.ncbi.nlm.nih.gov/pubmed/22121091>
4. Connolly EE, Beatty S, Loughman J, Howard AN, Louw MS, Nolan JM. Supplementation with all three macular carotenoids: response, stability, and safety. Invest Ophthalmol Vis Sci. 2011;52:9207-9217.  
<http://www.ncbi.nlm.nih.gov/pubmed/21979997>
5. Nolan JM, Akkali MC, Loughman J, Howard AN, Beatty S. Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment. Exp Eye Res. 2012. <http://www.ncbi.nlm.nih.gov/pubmed/22652506>
6. James Loughman, John M. Nolan, Alan N. Howard, Eithne Connolly, Katie Meagher, Stephen Beatty. The impact of macular pigment augmentation on visual performance using different carotenoid formulations. IOVS Nov 2012  
<http://www.ncbi.nlm.nih.gov/pubmed/23132800>
7. Meagher KM, Thurnham D, Beatty S, et al. Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. In: Br J Nutr. 2012 Dec 5:1-122012.  
<http://www.ncbi.nlm.nih.gov/pubmed/23211762>